Cargando…

Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience

BACKGROUND: Cure rates for chronic hepatitis C have improved dramatically with direct-acting antivirals (DAAs), but treatment barriers remain. We aimed to compare treatment initiation rates and barriers across both interferon-based and DAA-based eras. METHODS: We conducted a retrospective cohort stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nguyen, Peter, Vutien, Philip, Hoang, Joseph, Trinh, Sam, Le, An, Yasukawa, Lee Ann, Weber, Susan, Henry, Linda, Nguyen, Mindie H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Hepatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759739/ https://www.ncbi.nlm.nih.gov/pubmed/29333275 http://dx.doi.org/10.1136/bmjgast-2017-000181

Ejemplares similares

Rate of hepatocellular carcinoma surveillance remains low for a large, real-life cohort of patients with hepatitis C cirrhosis
por: Tran, Sally Ann, et al.
Publicado: (2018)

Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis
por: Yee, Brittany E, et al.
Publicado: (2015)

Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations
por: Gilman, Andrew J, et al.
Publicado: (2018)

Systematic review and meta-analysis: real-world effectiveness of direct-acting antiviral therapies in chronic hepatitis C genotype 3 in Asia
por: Wei, Bin, et al.
Publicado: (2018)

Long-term follow-up and suboptimal treatment rates of treatment-eligible chronic hepatitis B patients in diverse practice settings: a gap in linkage to care
por: Vu, Vinh D, et al.
Publicado: (2015)

Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study
por: Ladenheim, Maya R, et al.
Publicado: (2016)

Primary hepatic large B-cell lymphoma following direct-acting antiviral treatment for hepatitis C
por: Zaimi, Yosra, et al.
Publicado: (2021)

Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis
por: Zhang, Bing, et al.
Publicado: (2015)

Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study
por: Volpato, Sofia, et al.
Publicado: (2017)

Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
por: Xiao, Fei, et al.
Publicado: (2015)

Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study
por: Chen, Qiushi, et al.
Publicado: (2019)

Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis
por: Nguyen, Nghia H, et al.
Publicado: (2016)

Screening and management of viral hepatitis and hepatocellular carcinoma in Mongolia: results from a survey of Mongolian physicians from all major provinces of Mongolia
por: Kim, Yoona A, et al.
Publicado: (2016)

Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States
por: Vutien, Philip, et al.
Publicado: (2016)

Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States
por: Nguyen, Vy H., et al.
Publicado: (2022)

Efficacy of antiviral therapy in patients with post-hepatitis C liver cirrhosis: is hyperuricaemia a potential adverse effect?
por: Elsayed, Amr, et al.
Publicado: (2020)

Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes
por: Mengshol, J A, et al.
Publicado: (2009)

Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study
por: Huang, Chung-Feng, et al.
Publicado: (2019)

Does COVID-19 infection significantly affect liver transplantation? Results of liver transplantation in the COVID-19 era at a single, high-volume centre
por: Moradi, Alimohammad, et al.
Publicado: (2023)

TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice
por: Martin, Perrine, et al.
Publicado: (2015)

Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis
por: Vutien, Philip, et al.
Publicado: (2017)

Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
por: Samson, Adel, et al.
Publicado: (2018)

HCV genome-wide analysis for development of efficient culture systems and unravelling of antiviral resistance in genotype 4
por: Pham, Long V., et al.
Publicado: (2022)

Outcomes of incoming and outgoing second opinions from a UK liver transplant centre
por: Parente, Alessandro, et al.
Publicado: (2022)

Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men
por: Thomson, Emma C, et al.
Publicado: (2010)

Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China
por: Zhang, H W, et al.
Publicado: (2008)

Identification of circulating microRNAs as potential biomarkers for hepatic necroinflammation in patients with autoimmune hepatitis
por: Saeki, Chisato, et al.
Publicado: (2022)

Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era
por: Zuckerman, Autumn, et al.
Publicado: (2018)

Updated upper limit of normal for serum alanine aminotransferase value in Vietnamese population
por: Huong, Nguyen Thi Cam, et al.
Publicado: (2022)

Combined small molecule and loss-of-function screen uncovers estrogen receptor alpha and CAD as host factors for HDV infection and antiviral targets
por: Verrier, Eloi R, et al.
Publicado: (2020)

A disrupted RNA editing balance mediated by ADARs (Adenosine DeAminases that act on RNA) in human hepatocellular carcinoma
por: Chan, Tim Hon Man, et al.
Publicado: (2014)

RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease
por: Afonso, Marta B, et al.
Publicado: (2021)

Barriers to implementation of stratified care in primary biliary cholangitis: a scoping exercise
por: Corrigan, Margaret, et al.
Publicado: (2019)

An educational tool for the prophylaxis of hepatic encephalopathy
por: Garrido, Maria, et al.
Publicado: (2017)

Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
por: Burm, Rani, et al.
Publicado: (2023)

Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis
por: Thiele, Maja, et al.
Publicado: (2013)

Hepatitis C elimination in the Netherlands (CELINE): study protocol for nationwide retrieval of lost to follow-up patients with chronic hepatitis C
por: Isfordink, Cas J, et al.
Publicado: (2020)

Cell-based cccDNA reporter assay combined with functional genomics identifies YBX1 as HBV cccDNA host factor and antiviral candidate target
por: Verrier, Eloi R, et al.
Publicado: (2023)

Loss of hepatic Mboat7 leads to liver fibrosis
por: Thangapandi, Veera Raghavan, et al.
Publicado: (2021)

Managing hepatic complications of pregnancy: practical strategies for clinicians
por: Morrison, Maura Alice, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uek64r8l20npj1gs6hajpjepj9